Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck Sharp & Dohme Corp
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Randomized Sitagliptin Withdrawal Study
In subjects with T2DM with inadequate glycemic control on metformin and sitagliptin, who initiate and titrate insulin glargine (LANTUS®), to assess the effect of continuing sitagliptin relative to wit...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
OS Study of Pembrolizumab (MK-3475) vs. SOC in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic NSCLC (Keynote 042)
1) To compare the overall survival (OS) in subjects with PD-L1 strongly positive, 1L advanced/metastatic NSCLC treated with pembrolizumab compared to standard of care (SOC) chemotherapies. 2) To co...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Adult Lamivudine and Tenofovir Biocomparison Study for Pediatric Fixed Dose Combination Formulation
To evaluate the comparative bioavailability of: 1.lamivudine 300mg: a. adult marketed tablets to the investigational oral pediatric uncoated/coated granules-fasted conditions b.investigational oral...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Phase-II Study of MK-1029 added to Montelukast in Adults with Uncontrolled Asthma
To demonstrate that MK-1029, compared with placebo, increases lung function when added to montelukast.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A clinical trial to test if the combination of ertugliflozin with Sitagliptin is safe when compared to placebo in patients with Type 2 Diabetes whose sugar levels are not well controlled by diet and excercise
In subjects with T2DM and inadequate glycemic control on diet and exercise, after 26 weeks: 1. To assess the A1C-lowering efficacy of ertugliflozin 15 mg q.d. plus sitagliptin 100 mg q.d. relative to...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
After 30 weeks, in elderly patients with T2DM with inadequate glycemic control on diet and exercise: 1) To assess the effect of sitagliptin compared with glimepiride on A1C. 2) To assess the effe...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A clinical trial to test if the drug ertugliflozin is safe and effective when compared to placebo in patients with Type 2 Diabetes and stage 3 chronic kidney disease whose sugar levels are not well controlled by their current treatment
In subjects with T2DM and inadequate glycemic control on standard diabetes therapy with a Visit 3/Week -2 eGFR of ≥30 to <60 mL/min/1.73m2, after 26 weeks: 1. To assess the A1C-lowering efficacy of t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Phase IIa trial of MK0646 Tx in combo w/ Irinotecan vs Cetuximab and Irinotecan for mRC patients
To compare PFS of patients with wtKRAS mRC with High IGF-1/Low IGF-2 levels when treated with Dalo + Irino relative to patients treated with Cetux + Irino
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA
MAJ Il y a 5 ans
A Randomized, Active-Controlled Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly with Peginterferon alfa-2b and Ribavirin in Treatment-Naïve and Prior Treatment Failure to Pegylated Interferon and Ribavirin Patients with Chronic Genotype 1 Hepatitis C Virus Infection
To evaluate the antiviral activity of each of the four arms of MK-5172(arms 1, 2, 3, and 4) administered in combination with Peg-IFN alfa-2b and RBV as assessed by the proportion of patients achieving...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp
MAJ Il y a 5 ans
A Clinical Trial testing Caspofungin versus another antifungal antibiotic (Amphotericin B Deoxycholate) in The treatment of fungal infections in Newborns and Infants less than 3 months of age
Objective: To compare caspofungin to amphotericin B deoxycholate with respect to the efficacy endpoint of fungal-free survival at the 2-week post-therapy follow-up visit (i.e., the proportion of pati...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
9
10
11
12
13
14
15
16
17
18
Suivant